NervGen's groundbreaking NVG-291 treatment for spinal cord injury is currently in trials with FDA Fast Track Designation.

Shares in the company were up 7% at market open following the first approval for a non-invasive spinal cord stimulator for ...

Elezanumab (ABT-555) is under development for the treatment of acute ischemic stroke, acute traumatic cervical spinal cord injury and Cerebral infarction. It is administered as an intravenous infusion ...

Immune globulin (human) is under clinical development by CSL and currently in Phase III for Chronic Lymphocytic Leukemia (CLL).

While typical infections in spinal cord injury ... primary endpoint for the study focused on the change in the American Spinal Injury Association (ASIA) (motor score at one year after SCI ...

When untreated, this injury ... chronic UCL injuries. Our primary purpose was to compare nonoperative treatment with surgical repair and surgical reconstruction of thumb UCL injuries. A secondary ...

chronic, local immune-mediated esophageal disease. NovaGo Therapeutics AG informed about the publication of results for the investigation of NG101 in acute spinal cord injury patients. The primary ...

ed.ac.uk Myocardial injury ... primary and secondary endpoints,2–4 it has not been widely adopted in clinical practice, and the frequency and implications of subtypes of acute myocardial infarction ...

A Phase I clinical trial led by researchers at University of California San Diego School of Medicine has demonstrated the ...